---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-006120"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:14:00.858176+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Monopar Q1 net loss $2.4M; camsirubicin dose-escalation continues; Validive trial discontinued

## Summary
- Net loss of $2.4M ($0.19/share) for Q1 2023, vs $2.5M ($0.19/share) in Q1 2022.
- Cash, equivalents and short-term investments $11.7M as of March 31, 2023; runway through June 2024.
- Camsirubicin Phase 1b enrolling 5th dose cohort (650 mg/m²); no drug-related cardiotoxicity observed to date.
- Validive Phase 2b/3 VOICE trial discontinued after DSMB found it did not meet 15% efficacy threshold.
- MNPR-101 RIT preclinical studies show high tumor uptake; FIH imaging study targeted by end of 2023.

## SEC filing metadata
- accession: 0001654954-23-006120
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000165495423006120/0001654954-23-006120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000165495423006120/mnpr_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-006120
- JSON: https://secwatch.observer/filing/0001654954-23-006120.json
- Plain text: https://secwatch.observer/filing/0001654954-23-006120.txt

## Key facts
- Earnings Releases
  Monopar Therapeutics reported first quarter ended March 31, 2023 results: net income $2.4 million, EPS $0.19 per share.
  - Period: first quarter ended March 31, 2023
  - Net income: $2.4 million
  - EPS: $0.19 per share
  - Result: reported results
  source text: Net loss for the first quarter of 2023 was $2.4 million or $0.19 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000165495423006120/0001654954-23-006120-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.